Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARKLE: Crizanlizumab in Sickle Cell Disease Patients With Frequent Vaso-Occlusive Crises
NCT06439082Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Oct 2024
- Primary completion
- Jul 2029
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in sickle cell disease (SCD) comparing Crizanlizumab (SEG101) at 5.0 mg/kg with Placebo (2 arms). Primary endpoint: Annualized rate of vaso-occlusive crises that are healthcare professional-managed at 1 year. Started Oct 2024; status: recruiting.
02
Drugs
crizanlizumab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT06439082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06439082.